Document:

EXHIBIT 10.1

             SEPARATION AGREEMENT AND MUTUAL RELEASE OF ALL CLAIMS

EMPLOYEE:                                                Allen L. Shulman

DATE OF HIRE:                                            November 5, 2001

DATE OF TERMINATION:                                     October 18, 2005

     THIS  SEPARATION  AGREEMENT AND MUTUAL  RELEASE OF ALL CLAIMS  (hereinafter
"the Agreement") is entered into by and among  Interland,  Inc. ("the Company"),
and the employee identified above ("Employee").

                                   BACKGROUND

     Employee and the Company are  terminating  their  employment  relationship,
including without  limitation their employment  relationship  under that certain
Employment  Agreement  between  Company and Employee  dated November 1, 2001, as
amended  from time to time (the  "Employment  Agreement"),  and desire to settle
fully and finally all  differences  between them that may arise out of or relate
to Employee's  employment  with the Company and all other claims Employee has or
may have through the Effective Date.

     NOW,  THEREFORE,  in consideration of this recital,  the mutual  agreements
contained  herein  and  other  good and  valuable  consideration,  the  receipt,
adequacy and  sufficiency of which is hereby  acknowledged,  the parties to this
Agreement hereby agree, promise and covenant as to each of the following:

1. Capacity to Execute.  Each of the parties represents and warrants that she/he
or it is legally viable and competent to enter into this  Agreement,  is relying
on  independent  judgment  and the  advice  of  legal  counsel  and has not been
influenced,  pressured  or  coerced  to any  extent  whatsoever  in making  this
Agreement by any  representations  or statements  made by the Company and/or any
person or persons representing the Company,  and that the individuals  executing
this  Agreement  on her/his or its behalf are  authorized  to do so. Each of the
parties  further  represents  and  warrants  that  she/he  or it has  not  sold,
assigned, transferred,  conveyed or otherwise disposed of all or any part of the
claims released hereunder, whether known or unknown.

2. Specific Consideration Provided to Employee.

(a) In exchange for the release  provided  hereunder and other good and valuable
consideration,  and following the Effective Date assuming that this Agreement is
not revoked  pursuant  to Section 12, in lieu of any  payments or benefits to be
provided pursuant to the Employment Agreement,  the Company will pay Employee an
amount in cash  equal to  $362,500  less all  legally  required  deductions  and
withholdings.  The  Severance  Amount  will be paid  out in a  single  lump  sum
promptly following the Effective Date, as defined in Section 12(e).

<PAGE>

(b) In addition,  Company  undertakes to indemnify  and defend  Employee for any
claims asserted against the Employee arising out of Employee's  actions taken on
behalf of the Company within the scope of Employee's  employment,  to the extent
and in the manner provided in the Company's  By-laws and the Minnesota  Business
Corporations Act.

(c) The severance  obligations  set forth in Section 2 are the total payment and
severance  obligations  under  this  Agreement,  which  represent  payments  and
obligations  that  Employee  would not otherwise be entitled to receive from the
Company.  Employee shall  accordingly also be entitled to receive salary through
the Date of  Termination,  pay for  accrued  but  unused  "time-off  with  pay",
reimbursement  for (or direct  payment of)  submitted  and  authorized  expenses
incurred  prior to the Date of  Termination  , and any benefits  provided in the
ordinary course by Company benefit plans. Accordingly,  Employee understands and
warrants that no further amount is or shall be due or claimed to be due from the
Company and/or from any other person or entity  released in Section 3 below with
respect to any claim or claims released in Section 3 below,  including,  but not
limited to, any and all claims for  attorneys'  fees and the costs of litigation
that  she/he may have under any  federal,  state or local law,  common law or in
equity;  provided,  however,  that the  severance  obligations  do not supersede
Employee's  rights to  indemnification,  advancement  of expenses,  or insurance
coverage  under  Section  2(b) of this  Agreement,  the  Company's  Bylaws;  the
Minnesota Business Corporation Act; applicable insurance policies; and any other
agreement,  contract,  law, or  otherwise  under  which  Employee is entitled to
indemnification,  advancement of expenses, or insurance coverage, for liability,
fees, and costs associated with claims asserted against the Employee.

(d) Employee  agrees to be responsible  for, and to pay in a timely manner,  all
federal,  state and local taxes that may be due on all payments  hereunder,  and
she/he  further  agrees to indemnify  and hold harmless the Company from any and
all costs and expenses that it may incur in the future if any federal, state, or
local  government  agency  or any  other  person  or  entity  asserts  that  any
withholding,  taxes,  or other  amounts  should have been paid by the Company in
connection with this payment, and such indemnification shall include, but not be
limited to, any taxes,  interest,  penalties,  and  reasonable  attorneys'  fees
incurred by the Company in connection therewith.

(e) In  consideration  of the severance  payment provided for by this Agreement,
Employee hereby  surrenders to the Company for cancellation each and every stock
option granted to Employee prior to the date of this Agreement, as summarized on
EXHIBIT A hereto,  and which stock  options  Employee  represents  have not been
exercised, sold, hypothecated or otherwise transferred.

(f)  Employee  agrees to  cooperate  with the  Company as a fact  witness in any
litigation to which the Company is a party and agrees to appear, for interviews,
deposition testimony and trial testimony,  with reasonable advance notice, for a
per diem payment of $1,000 per day,  which rate  approximates  Employee's  daily
rate  of pay  as of the  date  of  this  Agreement,  plus  reimbursement  of any
reasonable and necessary out-of-pocket fees and expenses.

3. Mutual Release of all Claims by the Parties.

(a) In consideration of the concessions provided for in Section 2 and other good
and valuable consideration,  the receipt,  adequacy, and sufficiency of which is

<PAGE>

hereby  acknowledged,  Employee and her/his  heirs,  executors,  administrators,
agents,  assigns,   receivers,   attorneys,   servants,  legal  representatives,
predecessors  and  successors  in  interest,  regardless  of form,  trustees  in
bankruptcy or otherwise, wards, and any other representative or entity acting on
her/his or their behalf, pursuant to, or by virtue of the rights of any of them,
do hereby now and forever  unconditionally  release,  discharge,  and acquit the
Company  and any parent,  subsidiary  or related  companies,  and any and all of
their  employees,  agents,   administrators,   assigns,  receivers,   attorneys,
servants,  legal  representatives,  affiliates,  predecessors  and successors in
interest,  regardless of form, and trustees in bankruptcy or otherwise, from any
and all claims, rights,  demands,  actions,  suits, damages,  losses,  expenses,
liabilities, indebtedness, and causes of action, of whatever kind or nature that
accrued from the  beginning of time through the  Effective  Date,  regardless of
whether  known or unknown,  and  regardless  of whether  asserted by Employee to
date,  including,  but not  limited  to, all claims for or  relating to assault,
battery,   negligence,   negligent  hiring,   negligent   retention,   negligent
supervision,   negligent  training,   negligent  or  intentional  infliction  of
emotional distress,  false imprisonment,  defamation (whether libel or slander),
personal injury, bodily injury, bad faith, pain and suffering, medical expenses,
wage and hour,  lost income and  earnings  (including,  but not limited to, back
pay, front pay and any other form of present or future income,  benefits  and/or
earnings),  equitable reinstatement,  breach of any express or implied contract,
breach of the covenant of good faith and fair  dealing,  workers'  compensation,
wrongful termination,  wrongful demotion,  wrongful failure to promote, wrongful
deprivation  of  a  career  opportunity,   discrimination  (including  disparate
treatment and disparate impact),  hostile work environment,  quid pro quo sexual
harassment,  retaliation,  any  request to submit to a drug or  polygraph  test,
and/or  whistleblowing,  whether said claim(s) are brought pursuant to Title VII
of the Civil  Rights Act of 1964,  the Civil Rights Act of 1991,  42 U.S.C.  ss.
1981, the Employee  Retirement  Income  Security Act of 1974, the Equal Pay Act,
the  Pregnancy  Discrimination  Act,  the  Fair  Labor  Standards  Act,  the Age
Discrimination  in Employment  Act, the  Americans  with  Disabilities  Act, the
Family and Medical Leave Act or any other constitutional,  federal,  regulatory,
state or local law,  or under the common  law or in equity.  Provided,  however,
that this Section 3(a) will not terminate Employee's right to indemnification to
the extent allowed by Applicable Law, for advancement of expenses,  or insurance
coverage under the Company's  Bylaws;  the Minnesota  Business  Corporation Act;
applicable  insurance  policies;  and any other  agreement,  contract,  law,  or
otherwise  under which Employee is entitled to  indemnification,  advancement of
expenses, or insurance coverage, for liability,  fees, and costs associated with
claims  asserted  against the  Employee  regardless  of whether  such claims are
asserted against Employee prior to or following the Effective Date.

(b) In consideration  of the concessions  provided for in Section 3(a) and other
good and valuable consideration, the receipt, adequacy, and sufficiency of which
is hereby  acknowledged,  the  Company  and any  parent,  subsidiary  or related
companies, and any and all of their employees, agents, administrators,  assigns,
receivers, attorneys, servants, legal representatives,  affiliates, predecessors
and  successors  in interest,  regardless  of form,  trustees in  bankruptcy  or
otherwise, and any other representative or entity acting on its or their behalf,
do  hereby  now and  forever  unconditionally  release,  discharge,  and  acquit
Employee and his heirs, executors, administrators, agents, receivers, attorneys,
servants,  legal  representatives,  predecessors  and  successors  in  interest,
regardless of form, trustees in bankruptcy or otherwise,  wards, pursuant to, or
by  virtue  of the  rights  of any of  them,  from any and all  claims,  rights,
demands, actions, suits, damages, losses, expenses,  liabilities,  indebtedness,

<PAGE>

and causes of action, of whatever kind or nature, of which the Company presently
has knowledge,  arising out of or related to acts  commencing from the beginning
of time through the Effective  Date,  including,  but not limited to, any claims
under other constitutional,  federal,  regulatory,  state or local law, or under
the common law or in equity.  The burden of proving the actual  knowledge of the
Company of such events,  occurrences or omissions giving rise to a claim against
Employee  shall be the Employee's  burden,  and shall only be established by the
actual,  conscious  knowledge  of (a) an  officer of the  Company  who is a Vice
President of the Company or higher,  or (b) the General  Counsel of the Company,
or (c) the Board of Directors of the Company, or (d) an appropriate committee of
the  Board  of  Directors  constituted  for a  purpose  related  to the  events,
occurrences  or omissions at issue.  Provided,  however,  that this Section 3(b)
will not  terminate the Company's  right to defend  against any claims  asserted
pursuant to the rights reserved by Employee in Section 3(a).

4. Covenant Not-to-Sue.

(a) Employee  covenants and agrees not to file or initiate a lawsuit against the
Company in regard to any  claims,  demands,  causes of action,  suits,  damages,
losses and expenses  released pursuant to Section 3(a), and Employee will ask no
other person or entity to initiate such a lawsuit on her/his behalf. If Employee
breaches this covenant and agreement, Employee must immediately repay and refund
to the Company all payments she/he received  pursuant to Section 2, and Employee
shall also indemnify and hold harmless the Company,  any related companies,  and
any of their officers, owners, directors,  employees and agents from any and all
costs incurred by any and all of them,  including  their  reasonable  attorneys'
fees, in defending  against any such  lawsuit.  Notwithstanding  the  foregoing,
Employee  retains  the right to bring suit  against  the  Company to enforce the
provisions  of this  Agreement  and to enforce  his  rights to  indemnification,
advancement of expenses,  or insurance  coverage under the the Company's Bylaws;
the Minnesota Business Corporation Act; applicable  insurance policies;  and any
other agreement, contract, law, or otherwise under which Employee is entitled to
indemnification,  advancement of expenses, or insurance coverage, for liability,
fees, and costs associated with claims asserted against the Employee.

(b) The Company  covenants and agrees not to file or initiate a lawsuit  against
Employee in regard to any claims,  demands,  causes of action,  suits,  damages,
losses and expenses  released  pursuant to Section 3(b) and the Company will ask
no other person or entity to initiate such a lawsuit on her/his  behalf.  If the
Company  breaches this covenant and agreement,  the Company shall also indemnify
and hold harmless  Employee,  any related  entities,  and any of their officers,
owners,  directors,  employees and agents from any and all costs incurred by any
and all of them,  including  their  reasonable  attorneys'  fees,  in  defending
against any such  lawsuit.  Provided,  however,  that this Section 3(b) will not
terminate the Company's right to defend against any claims asserted  pursuant to
the rights reserved by Employee in Sections 3(a) and 4(a).

5. No  Proceedings  Initiated.  Employee  represents  and warrants  that neither
she/he nor anyone acting on her/his  behalf has filed or initiated any charge or
claim against the Company in any administrative or judicial proceeding.

6.  Return of  Company  Property.  Employee  further  promises,  represents  and
warrants that he has returned t:

(a) all  property  of the  Company,  including,  but not limited to, any and all
files, records, credit cards, keys, identification cards/badges, computer access

<PAGE>

codes, computer programs,  instruction manuals,  equipment (including computers)
and business plans; (b) any other property which Employee  prepared or helped to
prepare in connection with Employee's  employment with the Company;  and (c) all
documents,  including logs or diaries (except  personal  diaries),  all tangible
materials,  including audio and video tapes, all intangible materials (including
computer  files),  and any and all copies or  duplicates of any such tangible or
intangible materials,  including any duplicates,  copies, or transcriptions made
of audio or video tapes, whether in handwriting or typewritten,  that are in the
possession,  custody or control of Employee or her/his attorneys, agents, family
members, or other  representatives,  which are alleged to support in any way any
of the claims  Employee has released  under this  Agreement,  including  but not
limited  to,  all  audio  and  videotapes   involving  any  officer,   director,
shareholder,  executive, manager, employee, agent, representative or attorney of
the Company, The parties acknowledge that Employee, for the purpose of preparing
for litigation, has been provided materials by counsel for the Company, and that
Employee  shall be entitled to retain such  materials,  solely for such purpose,
until their return is requested by the Company or its counsel.

7. No Voluntary  Assistance.  Employee  hereby  covenants and agrees that she/he
will not voluntarily assist, support, or cooperate with, directly or indirectly,
any entity or person alleging or pursuing any claim,  administrative  charge, or
cause of action against the Company,  including without  limitation by providing
testimony or other information,  audio or video recordings, or documents, except
under compulsion of law. If compelled to testify, nothing contained herein shall
in any way inhibit or interfere  with  Employee  providing  completely  truthful
testimony.  Nor shall anything herein prevent  Employee's full  cooperation with
any investigation or other proceeding by the EEOC or any other federal, state or
local governmental agency.

8. Attorneys' Fees and Costs.  The parties to this Agreement,  individually  and
collectively,  shall be responsible for their own attorneys' fees and costs, and
for  extinguishing  any  attorneys'  liens  filed by their  counsel  of  record.
Employee  understands  and agrees that the  payments  contemplated  in Section 2
include and encompass any and all claims with respect to attorneys' fees, costs,
and expenses for and by any and all  attorneys  who have  represented  him, with
whom  she/he has  consulted  or who have done  anything in  connection  with the
subject matter of this Agreement or any of the claims being released  hereunder.
Provided,  however,  that the foregoing does not supersede  Employee's rights to
indemnification,  advancement of expenses,  or insurance coverage under the this
Agreement;  the  Company's  Bylaws;  the  Minnesota  Business  Corporation  Act;
applicable  insurance  policies;  and any other  agreement,  contract,  law,  or
otherwise  under which Employee is entitled to  indemnification,  advancement of
expenses, or insurance coverage, for liability,  fees, and costs associated with
claims asserted against the Employee.

9. No  Admission  of  Liability.  The parties  agree and  acknowledge  that this
Agreement  is a full and  complete  compromise  of the matters  released  herein
between the parties hereto;  that neither the releases nor the  negotiations for
this Agreement and the settlement  embodied herein,  including all statements or
communications made to date, shall be considered admissions by them.

10.  Other  Obligations.  Employee  acknowledges  that  the  provisions  of  his
Employment Agreement, Confidentiality,  Invention Assignment and Non-Competition

<PAGE>

Agreement  and other  agreements  with the  Company  which,  by their  terms are
intended to survive the  termination of the employment  relationship,  remain in
full  force  and  effect  and are not  waived  or  terminated  by virtue of this
Agreement.

11. Enforcement of this Agreement.

(a) In the event of a default or breach of this Agreement, each party is free to
pursue  whatever legal or equitable  remedies that may be available to him or it
to seek judicial enforcement of this Agreement, whether by injunction,  specific
performance, an action for damages or otherwise.

(b) Notwithstanding  Section 8 above, the parties expressly acknowledge that any
and all  attorneys'  fees and  expenses  incurred in any  proceeding  brought to
enforce this Agreement as a result of a breach thereof shall  constitute part of
the damages recoverable for any such breach.  Therefore, the prevailing party in
any action to enforce this  Agreement,  in addition to any other relief granted,
shall be entitled to recover its reasonable  costs,  including,  but not limited
to, attorneys' fees, expenses and costs.

12. OWBPA Rights.

(a)  Employee  is  advised  to seek legal  counsel  regarding  the terms of this
Agreement.  Employee acknowledges that he/she has either sought legal counsel or
has  consciously  decided not to seek legal  counsel,  contrary to the Company's
advice, regarding the terms and effect of this Agreement.

(b) Employee  acknowledges  that this Agreement  releases only those claims that
exist as of the date of Employee's execution of this Agreement.

(c) Employee  acknowledges that he/she may take a period of 21 (twenty-one) days
from the date of receipt of this  Agreement  within  which to consider  and sign
this Agreement. If Employee fails to sign this Agreement,  Employee shall not be
entitled to the consideration provided in Section 2.

(d) Employee  acknowledges that he/she will have seven (7) days from the date of
signing  this  Agreement  to revoke the  Agreement  in  writing in its  entirety
("Revocation Period").  Employee acknowledges that the Agreement will not become
effective or enforceable until the Revocation  Period has expired.  In the event
the Employee chooses to revoke this Agreement,  within the Revocation Period, he
or she will:

     (1) Revoke the  entire  Agreement  in a signed  writing,  delivered  to the
following  person on or before the seventh  (7th) day after he/she  executed the
Agreement:

         Interland Human Resources
         303 Peachtree Center Ave., Suite 500
         Atlanta, GA  30303

     (2)  Forfeit all  severance  and  payment  rights of the  Company  that are
contemplated by this Agreement; and

<PAGE>

     (3)  Return  the full  amount of  consideration  received,  if any,  to the
Company along with the signed writing.

(e) The "EFFECTIVE  DATE" of this Agreement  shall be the eighth (8th) day after
the date Employee signs the Agreement, assuming the Employee has not revoked the
Agreement in writing within the Revocation Period.

13.   Employee   expressly   acknowledges   that  the  payments  and  the  other
consideration that he/she is receiving under this Agreement  constitute material
consideration  for his/her execution of this Agreement,  and represent  valuable
consideration to which he/she would not otherwise be entitled.

14. Jurisdiction.  The laws of the State of Georgia shall govern this Agreement,
unless  pre-empted by any applicable  federal law controlling the review of this
Agreement.

15.  Advice of  Attorneys.  The parties  acknowledge  that they have fully read,
understood and  unconditionally  accepted this Agreement  after  consulting with
their  attorneys or having the  opportunity  to consult  with an  attorney,  and
acknowledge  that this  Agreement is mutual and binding upon all parties  hereto
regardless  of the extent of damages  allegedly  suffered  by any of the parties
hereto.

16. Counterparts. This Agreement may be signed in counterpart originals with the
same force and effect as if signed in a single original document.

17. Cooperation of the Parties. The parties to this Agreement agree to cooperate
fully  and to  execute  any  and all  supplementary  documents  and to take  all
additional  actions that may be necessary or  appropriate to give full force and
effect  to the basic  terms and  intent  of this  Agreement  and the  settlement
embodied herein.  Employee further agrees to fully cooperate with the Company in
any and all  investigations,  inquiries or  litigation  whether in any judicial,
administrative,  or public,  quasi-public or private forum, in which the Company
is  involved,  whether or not  Employee is a defendant  in such  investigations,
inquiries,  proceedings  or  litigation.  Employee  shall  provide  truthful and
accurate testimony, background information, and other support and cooperation as
the Company may reasonably request.

18.  Modification  in Writing Only.  Neither this Agreement nor any provision of
this  Agreement  may be modified or waived in any way except by an  agreement in
writing signed by each of the parties hereto  consenting to such modification or
waiver.

19. No False  Statements or  Misrepresentation.  Employee and the Company hereby
warrant  and  represent  that  they  have  not  made  any  false  statements  or
misrepresentations in connection with this Agreement.

20.  Headings and Captions.  The headings and captions used in the Agreement are
for convenience of reference only, and shall in no way define, limit, expand, or
otherwise affect the meaning or construction of any provision of this Agreement.

21. Miscellaneous.  Any notice required or permitted to be given by either party
to the other party may be given by  certified  mail or  overnight  courier if to

<PAGE>

Employee to Employee's  home address  identified  above and if to the Company to
the Company at the following  address or to the Company's  headquarters  address
(if it should cease to be at the following address):

                           Interland, Inc.
                           303 Peachtree Center Ave., Suite 500
                           Atlanta, GA  30303
                           Attn: Human Resources Department

                           With a copy to:

                           Interland, Inc.
                           303 Peachtree Center Ave., Suite 500
                           Atlanta, GA  30303
                           Attn: Legal Department

IN WITNESS WHEREOF, the undersigned have executed this Agreement.

EMPLOYEE:

/s/ Allen L. Shulman
-------------------------------
Allen L. Shulman

Date: 10/18/05
     --------------------------

INTERLAND, INC.

By: /s/ Jeffrey M. Stibel
    ----------------------------

Its: CEO & President
     ----------------------------

Date: 10/18/05
     ----------------------------

<PAGE>

                                                     EXHIBIT A
                                             Outstanding Stock Options
<TABLE>
<CAPTION>
<S>                           <C>        <C>           <C>      <C>            <C>        <C>          <C>

                              Grant        Grant date    Plan      Number        Price    Exercised    Outstanding
Shulman, Allen L.             01000620     10/17/2002  2002/NQ     2,083.333   $17.5000     0.000        2,083.333
                              01001286      1/13/2003  2002/NQ     2,093.750   $11.0000     0.000        2,093.750
                              95000470      11/6/2001  95OP/ISO   12,000.000   $16.2000     0.000       12,000.000
                              95014597      1/15/2002  95OP/NQ     5,605.400   $21.4000     0.000        5,605.400
                              95014598      1/15/2002  95OP/ISO    7,394.600   $21.4000     0.000        7,394.600
                              N1000620     10/17/2002  2002/NQ     7,916.667   $17.5000     0.000        7,916.667
                              N1000720       2/3/2005  2002/NQ    20,000.000    $2.6200     0.000       20,000.000
                              N1001286      1/13/2003  2002/NQ    15,406.250   $11.0000     0.000       15,406.250
                              N1001742      7/29/2004  2002/NQ     6,000.000    $3.3300     0.000        6,000.000

</TABLE>EXHIBIT 10.11

* Portions  of this  document  have
been  omitted  and are subject to a
request for confidential  treatment
with the  Securities  and  Exchange
Commission.

                                   LICENSING &
                              TECHNOLOGY TRANSFER
                                   AGREEMENT

BIONOVO INC.
UNITED BIOTECH CORPORATION

                                       1
<PAGE>

                                NOVEMBER 6, 2003

                         LICENSING & TECHNOLOGY TRANSFER
                                   AGREEMENT

     THIS  AGREEMENT  (this  "Agreement")  is entered  into as of the 6th day of
     November, 2003 (the "Effective Date"), between:

     BIONOVO INC.,  U.S.A.  ("Bionovo"),  located at 2320 Woolsey St. Suite 100,
     Berkeley, CA 94705, U.S.A., and

     UNITED BIOTECH CORPORATION.  ("UBC"), a member of Maywufa Enterprise Group,
     located at Fl.5-2,  No. 167 Fu Hsin North Road, Taipei 105, Taiwan,  R.O.C.
     (Bionovo and UBC are referred to individually as a "Party" and collectively
     as the "Parties".)

WHEREAS

     A.   Bionovo  possesses  technology and know-how  referred to as MF101 (FDA
          IND#58267) for the indication of hot flashes and other symptoms of the
          climacteric,  osteoporosis,  breast cancer  prevention,  prevention of
          cardiovascular  disease and osteoarthritis in women with menopause and
          BZL101 (or FDA  IND#59521) for the indication of breast cancer and all
          other  solid  tumors,  as  described  in more detail on Exhibit A (the
          "Technology");

     B.   UBC desires to license the Technology in Territory; and

     C.   Bionovo is willing to grant UBC an exclusive, non-transferable license
          unless the transfer is made to a member of Maywufa  Enterprise  Group,
          license of the Technology if the Technology is developed in the manner
          and on the time table specified in this Agreement.

                                       2
<PAGE>

     NOW  THEREFORE  in  consideration  of the  mutual  promises  and  covenants
     contained herein, the parties to this Agreement agree as follows:

     ARTICLE 1  DEFINITIONS

     1.1  "Territory"  means  Taiwan with the  opportunity  to license for Asian
     countries  (including South Korea,  People's Republic of China,  Indonesia,
     Thailand,  Malaysia,  Singapore,  Vietnam,  and  Philippines)  exclusive of
     Japan.

     ARTICLE 2  LICENSE

          2.1  Bionovo  hereby  grants to UBC the  exclusive,  non-transferable,
               unless the  transfer  is made to a member of  Maywufa  Enterprise
               Group,  Licensing  Rights  with  respect  to both  MF101  for the
               indication  of hot  flash  with  menopause  and  BZL101  for  the
               indication of breast cancer in the Territory.

          2.2  Bionovo  warrants  that,  except for this  Agreement,  it has not
               entered  into  any  agreement  transferring  any  rights  in  the
               Technology in the Territory.

     ARTICLE 3  INDs; CLINICAL TRIALS; SUPPLY

          3.1  Bionovo will provide  detailed  information  to UBC regarding the
               Technology  as  reasonably  necessary to allow UBC to fulfill its
               obligations under this Agreement.

          3.2  Bionovo using the license fee, paid by UBC (as detailed in 4.1 of
               this agreement),  will file for intellectual  property protection
               ("patent application") at any relevant jurisdiction.

          3.3  During the  development  phase of this  Agreement,  Bionovo  will
               supply MF101 and BZL101 for oral administration  (either of them,
               individually,   a   "Pharmaceutical",   and   collectively,   the
               "Pharmaceuticals") to UBC at cost, at UBC's expense, as necessary
               to allow UBC to fulfill  its  obligation  under  this  Agreement.
               Before the development phase is completed, the Parties will enter
               into   a   mutually    agreeable   supply   agreement   for   the
               Pharmaceuticals,  which the Parties will negotiate in good faith.
               Bionovo assures UBC that the supply of Pharmaceuticals will be at
               least equal to those offered by Bionovo to any of its  customers.
               Bionovo shall provide verifiable cost information to UBC.

          3.4  At UBC's  expense,  within 120 calendar  days after the Effective
               Date,  UBC

                                       3
<PAGE>

               with the help of  Bionovo  will  apply to the  Taiwan  DOH for an
               investigational  new drug  license  ("IND")  for a phase II trial
               (the  "Phase  II  Trial")  for MF101  for the  indication  of hot
               flashes in peri-menopausal  and menopausal women and an IND for a
               Phase I trial (the "Phase I Trial") for BZL101 for the indication
               of  the   treatment   of  advanced   measurable   breast   cancer
               (collectively,  the  Phase I Trial  and the  Phase II  Trial  are
               referred to as the  "Trials").  The IND's will be filed under the
               UBC's sponsorship.

          3.5  Within 30 calendar  days after the  Effective  Date,  the Parties
               will  mutually  agree  of the  principal  investigators  for  the
               Trials.

          3.6  UBC  will  execute  the  Trials,  at its  expense,  according  to
               Bionovo's  protocols  as approved by the in Taiwan.  Bionovo will
               act as an  independent  auditor of the Trials and will  supervise
               the on going data collection.

          3.7  Bionovo  is  responsible  for  conducting   independent   quality
               assurance  studies of the  Pharmaceuticals  to ensure  compliance
               with US and  Taiwan  FDA  pharmaceutical  GMP  guidelines.  Those
               quality  assurance  studies  will  include:  (i)  microbiological
               panels,  (ii) heavy  metals,  (iii)  silica  gels of primers  and
               active  fractions,  (iv) HPLC/ MS and NMR  analysis,  and (v) bio
               analytical assays of activity.

          3.8  UBC will begin to execute each of the Trials, at its expense,  no
               later than 90 days after  Taiwan DOH  approval of the IND for the
               respective Trial. UBC will ensure that the principal investigator
               and the clinical  investigators,  inform Bionovo of any grade III
               or IV toxicity as defined by the US NCI common toxicity  criteria
               within 72 hours of any evidence of that  toxicity.  UBC will file
               all grade III and IV toxicities reports and all annual reports to
               the Taiwan  DOH.  After each of the Trials is  complete,  Bionovo
               will conduct an independent  data analysis and upon UBC's request
               Bionovo will provide UBC with a final Phase report for the Taiwan
               DOH.

          3.9  After each of the Trials is complete, the Parties will discuss in
               good faith  whether to continue to develop  either or both of the
               Pharmaceuticals.  If the Parties  agree to continue  with a Phase
               III trial for MF101 or a Phase II trial for  BZL101,  the Parties
               will have the same respective  responsibilities  (as described in
               this Article 3) for those trials as for the Trials.

                                       4
<PAGE>

          3.10  Before  UBC  executes  any phase III trial for MF101 or  BZL101,
                Bionovo,  at UBC's  expense,  will conduct  complete  Chemistry,
                Manufacturing and Control ("CMC") and absorption,  distribution,
                metabolism,  elimination  and  toxicology  ("ADMET")  studies to
                satisfy the additional Taiwan DOH guidelines for Phase III-level
                drug-manufacturing  protocols  and a final New Drug  Application
                ("NDA") process separate and different from any other regulatory
                authoritiy.  Bionovo  will provide all  available  CMC and ADMET
                data, at that time, at no additional expense to UBC.

          3.11  After  Taiwan DOH  approves  [the results of the Phase III trial
                of] a Pharmaceutical,  UBC will comply, at its expense, with any
                Taiwan  DOH  requirements  necessary  to permit  the  commercial
                marketing of that approved Pharmaceutical.

     ARTICLE 4  LICENSE FEE & ROYALTIES

          4.1   At the  signing  of this  Agreement,  the UBC  Parties  will pay
                Bionovo a  one-time,  non-refundable  fee of  US$150,000  at the
                signing of this agreement. Bionovo acknowledges that it received
                [*]  of  that  payment   before  signing  this   Agreement,   in
                consideration of its ongoing negotiation with the UBC Parties.

          4.2   Upon the completion of the phase II trial,  UBC will pay Bionovo
                an  amount  to be  discussed  at that  time in US$ in  order  to
                complete the additional specific  requirements for CMC by Taiwan
                DOH.  The  schedule  for the  payment  of the amount US$ will be
                determined  by a mutually  agreed  upon  timeline.  In the event
                Bionovo  did not  secure  additional  funding  for the  complete
                required CMC and ADMET, as required by US FDA, UBC will have the
                option to negotiate with Bionovo the independent  completion the
                above mentioned CMC and ADMET work. The terms of exercising this
                option  will be  mutually  agreed  upon  based  on  expense  and
                scientific evaluation of the process by both parties.

          4.3   UBC will pay to Bionovo a royalty fee (the "Royalty Fee") in the
                amount of [*] of total  monetary  consideration  received by UBC
                for

     --------
     * This information has been omitted and is subject to a request for
     confidential treatment with the Securities and Exchange Commission.

                                       5
<PAGE>

                Pharmaceuticals sold ("Net Sales").  However, if no patent(s) is
                granted  in the  territory  to one of the  Pharmaceuticals,  the
                Royalty Fee for the said Pharmaceutical  shall be [*] after five
                years from the time the product was launched.

          4.4   Bionovo and its representatives  (including  auditors) will have
                the right to examine  UBC's  books and record at any  reasonable
                time on  reasonable  notice  for the  purpose of  verifying  Net
                Sales.  All  expenses  arising  from  the  examination  of UBC's
                accounts  will  be  borne  by  Bionovo.  However,  if Net  Sales
                reported  to  Bionovo  are more  than [*]  less  than Net  Sales
                determined by independent  auditors engaged by Bionovo, UBC will
                pay 100% of the expenses of the  examination  of UBC'  accounts.
                All  information  and  documents  examined will be kept strictly
                confidential.

          4.5   UBC will pay the  Royalty Fee to Bionovo  quarterly,  within [45
                calendar] days after the end of each calendar quarter.

          4.6   All  payments  and  transfers  made  by UBC to  Bionovo  will be
                subject to the relevant  withholding  taxes prescribed by R.O.C.
                law.

          4.7   UBC will pay  pursuant to Article 3, within 30 calendar  days of
                the  date  of  any  reimbursement  request,  Bionovo's  expenses
                related  to (i)  quarterly  site  visit of each of the  clinical
                trials, (ii) semi annual investigator's  meeting for each of the
                clinical trials (iii) quarterly data review, (iv) any additional
                quality  assurance  work for the  drugs in trial,  (v)  protocol
                review and amendments of conferences,  (vi) future trial design,
                (vii) any Taiwan DOH  correspondence  that  requires  Bionovo to
                conference with at least two senior scientists for more than two
                hours,  (viii) end of data  analysis.  The fee schedule  will be
                [*]/ day or [*]/ hour for senior personnel, [*]/day or [*]/ hour
                for junior personnel and [*]/ day or [*]/ hour for data manager.
                In addition  UBC will pay all travel,  accommodations  and daily
                allowance.  UBC will pay any additional up to  [*] annually  for
                the  duration  of  the  development.  In  the  event  additional
                expenses  are accrued by Bionovo on UBC's behalf UBC and Bionovo
                will  mutually  agree to pay these  expenses.  The maximum total
                expenses  anticipated to be paid by UBC to Bionovo amount to [*]
                annually, for the duration of the drugs development.

     --------
     * This information has been omitted and is subject to a request for
     confidential treatment with the Securities and Exchange Commission.

                                       6
<PAGE>

     ARTICLE 5  USE OF LICENSE AND TECHNOLOGY

          5.1   UBC  guarantees  that it will use the License  Rights it obtains
                pursuant  to  this  Agreement   exclusively   for  the  purposes
                contemplated in this Agreement, and will not compete with itself
                in the Territory  with respect to MF101 and/or BZL101  through a
                related party.

          5.2   Bionovo  and  UBC  will  promptly   inform  each  other  of  any
                improvements  or new  indication(s)  to MF101 and/or BZL101,  or
                technology   relating  to  either  of  them   (hereinafter   the
                "Improvements")  that they may  develop  or be aware of and make
                available  for future  use by each of the  parties at no cost to
                any of the parties. UBC is authorized to use the License, any of
                their rights under this Agreement, or any of the Pharmaceuticals
                to develop and utilize any  Improvements to MF101 and/or BZL101.
                Bionovo will own all Improvements, and UBC will promptly execute
                any agreements,  assignments,  or other  documents  necessary to
                transfer ownership of any Improvements.

          5.3   UBC will  obtain and bear the cost of all  regulatory  licenses,
                authorizations,  and  consents  required  to fully  utilize  its
                Licensing Rights in the Territory.

     ARTICLE 6  OWNERSHIP OF PATENTS AND INTELLECTUAL PROPERTY RIGHTS

          6.1   As stated in  article  4.1,  Bionovo  at its  expense  will file
                patents  relating  to the  Technology  in Taiwan no later than 2
                months after the Effective  Date.  Bionovo will remain the owner
                of all  patents,  continuations,  improvements,  and  all  other
                intellectual property related to the Technology. Nothing in this
                Agreement will transfer any intellectual-property  rights to UBC
                other than the License.

          6.2   If there is any infringement on the intellectual property rights
                regarding the Technology in the Territory by a third party,  the
                Parties will use reasonable efforts to  collaboratively  enforce
                the patent  protection  received  of MF101 and  BZL101.  If both
                Parties  agree to take  action to remedy the  infringement,  the
                Parties will agree on the allocation of the related expenses and
                compensation  before taking any action. UBC may not initiate any

                                       7
<PAGE>

                enforcement proceeding without Bionovo's consent, which will not
                be unreasonably withheld.

          6.3   If there is any claim or action  alleging  that UBC'  activities
                relating  to the License are  infringing  upon the  intellectual
                property  rights  of  a  third  party,   the  Parties  will  use
                reasonable efforts to collaboratively  defend the rights granted
                to  UBC  in  the  License.  UBC  will  fund  the  defense  of an
                infringement claim relating to the License.

     ARTICLE 7  CONFIDENTIALITY

          7.1   The Parties  acknowledge  and agree  that,  in  performing  this
                Agreement's  terms,  each  Party  might  disclose  to the  other
                valuable  proprietary  information,  including this  Agreement's
                terms,  unpublished patent applications and related information,
                know-how,   technology,   technical  and   non-technical   data,
                including  but not  limited  to  research,  products,  services,
                development,  inventions,  processes,  designs,  specifications,
                photographs,   samples  of  Pharmaceuticals  or  other  items  ,
                documents,   marketing  information,  or  financial  information
                (collectively,  "Confidential  Information").  The Parties  will
                keep  all  Confidential  Information   confidential,   will  not
                disclose any  Confidential  Information to any third party,  and
                will  use   Confidential   Information  only  for  the  purposes
                specified   in  this   Agreement.   This  article  will  survive
                termination of this Agreement.

          7.2   Section  7.1's  confidentiality  obligations  will not  apply to
                Confidential  Information  where  it  can  be  demonstrated  and
                documented that: (i) the Confidential  Information is or already
                has become, part of the public domain at the time of disclosure,
                except by breach of the provisions of this  Agreement;  (ii) the
                Confidential  Information can be established by written evidence
                to have been already in the lawful  possession  of the receiving
                party,  prior to the  disclosure  by the other party and was not
                acquired,  directly or indirectly,  from the  disclosing  party;
                (iii) the  Confidential  Information is received by either party
                from a third party  without  restrictions  of disclosure or use,
                who  has  legitimate  and  lawful  possession  thereof  and  the
                unrestricted right to disclose such Confidential Information; or
                (iv) the Confidential Information is approved and authorized for
                release by the disclosing party in writing.

                                       8
<PAGE>

     ARTICLE 8  WARRANTIES & REPRESENTATIONS

          8.1   Bionovo warrants and represents as of the Effective Date:

               8.1.1  that it has been duly incorporated and is in good standing
                      pursuant to the laws of its jurisdiction of incorporation,
                      and it has the legal right and full power and authority to
                      execute and deliver and to perform its  obligations  under
                      this Agreement;

               8.1.2  that it either owns or otherwise  has the right to deliver
                      the Technology and supply MF101 and BZL101 to UBC and such
                      delivery or supply does not  infringe any  contractual  or
                      intellectual property rights of any third party;

               8.1.3  that except for this  Agreement,  it has not entered  into
                      any agreement transferring any rights in the Technology in
                      the Territory; and

               8.1.4  that it has  obtained  all  licenses,  authorizations  and
                      consents  required  for  the  proper  carrying  on of  its
                      business,  including the delivery of the  Pharmaceuticals,
                      and all such licenses, authorizations and consents if any,
                      are  valid  and  subsisting  and  there  are  no  existing
                      circumstances that can be reasonably foreseen as likely to
                      lead to their cancellation or suspension;

               8.1.5  that, to the best of Bionovo's knowledge,  the delivery of
                      the  Technology  transfer or supply of MF101 and BZL101 in
                      accordance  with the provisions of this agreement will not
                      infringe,  invalidate or otherwise contravene the terms of
                      any of the licenses,  authorizations, or consents referred
                      to in Article 8.1.4 nor of any applicable  U.S.  statutes,
                      laws, rules or all regulations; and

               8.1.6  that  the  information,  materials,  technical  data,  and
                      know-how  delivered  to  UBC  is  current,  accurate,  and
                      complete for the purposes of this Agreement.

          8.2   UBC warrants and represents as of the Effective Date:

               8.2.1  that it has been duly incorporated and is in good standing
                      pursuant to the laws of its jurisdiction of incorporation,
                      and it has the legal right and full power and authority to
                      execute and deliver and to perform its

                                       9
<PAGE>

                      obligations under this Agreement; and

               8.2.2  that it has  obtained  all  licenses,  authorizations  and
                      consents  required  for  the  proper  carrying  on of  its
                      business, including the receipt of the Pharmaceuticals and
                      the  execution  of  the  Trials,  if  any,  and  all  such
                      licenses,   authorizations  and  consents  are  valid  and
                      subsisting and there are no existing  circumstances  which
                      can be  reasonably  be foreseen as likely to lead to their
                      cancellation  or  suspension  or  to a  violation  of  any
                      applicable R.O.C. statute, law, rule or regulation.

          8.3   Bionovo and UBC will indemnify and hold harmless the other party
                from and against all loss,  damage,  and expense,  including but
                not limited to legal fees,  arising out of or in connection with
                any  claims  or  proceedings  resulting  from a breach  of their
                respective  warranties  and  representations  contained  in this
                Agreement,  and will provide all reasonable assistance requested
                by the other Party in response to said claims or proceedings.

     ARTICLE 9  TERM & TERMINATION

          9.1   This  Agreement's  term (the "Term") will begin on the Effective
                Date and will  continue  in force  for 10  years,  automatically
                renewing for successive periods of 3 years,  unless either party
                gives the other party 12 months  written notice of its intention
                not to renew.

          9.2   Either  Party has the right to terminate  this  Agreement if the
                applications for the necessary  Taiwanese  government  approvals
                for the sale of either Pharmaceutical are rejected.

          9.3   Either  Party has the right to terminate  this  Agreement if the
                other Party is in material breach of any  obligation,  warranty,
                or  representation  under this  Agreement  by giving 60 calendar
                days written  notice of its election to  terminate,  stating the
                nature of the  default  claimed.  The  defaulting  Party has the
                right,  during the 60-day period,  to correct the default and if
                that default is so corrected,  this  Agreement  will continue in
                full force and effect as if that notice had not been  given.  If
                the default is not corrected within that sixty-day  period,  the
                Party  that  provided  notice  of the  default  has the right to
                terminate  this  Agreement   immediately   upon  notice  to  the
                defaulting Party.

                                       10
<PAGE>

          9.4   Either  Party  has  the  right  to  terminate   this   Agreement
                immediately  and without notice if: (i) an order is made for the
                winding-up of the other Party;  (ii) an effective  resolution is
                passed for the  winding-up  of a Party,  other than that Party's
                voluntary  winding-up solely for the purposes of amalgamation or
                reorganization;  or (iii) an administrative receiver or receiver
                is appointed  over the whole or  substantially  all of the other
                Party's assets.

     ARTICLE 10  EFFECT OF TERMINATION

          10.1  This  Agreement's  termination or expiration will not affect any
                rights that have accrued to a Party during the Term.

          10.2  This Article 10 will survive this Agreement's termination.

     ARTICLE 11  DISPUTE RESOLUTION & GOVERNING JURISDICTION

          11.1  This  Agreement  is  governed  by and  will  be  interpreted  in
                accordance  with  California  law,  and the parties  irrevocably
                agree that the state and federal courts of California  will have
                jurisdiction  to  enforce  any  award of the  arbitral  tribunal
                described in Section 11.2.

          11.2  The Parties  will  resolve any  dispute,  controversy,  or claim
                related to this Agreement or the  transactions  contemplated  by
                this  Agreement (a "DISPUTE")  using the procedures set forth in
                this Article 11, as the sole and exclusive remedy in lieu of any
                other available remedies.

          11.3  The  Parties  will  attempt in good faith to resolve any Dispute
                promptly  by  negotiation.  All  negotiations  pursuant  to this
                clause  will  be  confidential,   and  with  respect  to  claims
                involving  litigation  or  anticipated   litigation  with  third
                parties, will be subject to the joint defense or common interest
                privilege and/or other privileges. The negotiations will also be
                treated as compromise  and settlement  negotiations  pursuant to
                the full  extent  of the  rules of  evidence  applicable  in any
                proceeding  regarding the Dispute.  If the Parties are unable to
                resolve  a  Dispute  within  five  business  days  after a Party
                receives a request in  writing  to begin  negotiating  regarding
                that   Dispute,   either   Party  may  give   notice   requiring
                arbitration.  The arbitration

                                       11
<PAGE>

                will be conducted  according to the  provisions  of this Article
                11.

          11.4  Any Dispute that the Parties  have not  resolved by  negotiation
                will  be  settled  by an  arbitral  tribunal  in San  Francisco,
                California.  The arbitral  tribunal will conduct the arbitration
                in  accordance  with  the  Commercial  Arbitration  Rules of the
                American Arbitration  Association (the "AAA") as supplemented by
                (A) the AAA optional rules for emergency  measures of protection
                and (B) if the amount of disclosed aggregate value of all claims
                exceeds $1 million  (excluding  interest,  arbitration  fees and
                costs),  the AAA optional  procedures  for large  disputes.  The
                foregoing  rules  and  procedures  as in effect  (including  any
                amendments  throughout  the period of the  arbitration)  will be
                deemed to be  incorporated  by reference into this Section 11.4.
                The arbitral  tribunal  will be composed of a single  arbitrator
                mutually  agreed by the  Parties.  If the  Parties are unable to
                reach an  agreement  on the person to appoint as the  arbitrator
                within 30 calendar days after the  arbitration is filed,  either
                Party may request the Center for Dispute  Resolution appoint the
                arbitrator.  If the  arbitrator  is unable to serve,  his or her
                replacement will be selected in the same manner provided in this
                Section 11.4.

          11.5  The parties will have the right to enforce any awards determined
                by the  arbitral  tribunal  by filing  suit only in any state or
                federal  court in the  state  of  California  and to enter  that
                judgment in any court  necessary or appropriate to enforce same.
                By execution and delivery of this agreement, each of the parties
                (on  behalf  of  itself   and  its   affiliates)   accepts   the
                jurisdiction of those courts and irrevocably  agrees to be bound
                by any action of those courts in connection with this agreement.
                Each party  hereby  waives any  objection it may have based upon
                lack  of  personal   jurisdiction,   improper  venue,  or  forum
                non-conveniens.

     ARTICLE 12 MISCELLANEOUS

          12.1  NOTICE.  Any  notice,  consent or  communication  authorized  or
                required to be given under or for the purposes of this Agreement
                will  be  sent  by  registered  airmail,  e-mail,  or fax to the
                recipient at the following addresses:

                                       12
<PAGE>

                To Bionovo at: 2320 Woolsey St, Suite 100, Berkeley, CA 94705,
                USA

                         Contact: Isaac Cohen
                         Address: 2320 Woolsey St, Suite 100, Berkeley, CA
                                  94705, USA
                         Fax:     +1-510- 843- 7379
                         E-mail:  Isaac@bionovo.com

                To UBC at:

                         Contact: Jeffrey Yang
                         Address: Fl.5-2, No. 167 Fu Hsin North Road,
                                  Taipei 105, Taiwan, R.O.C.
                         Fax:     +886-2-2545-5763
                         E-mail:  jyang@ubc.com.tw

               Any such notice, consent, or communication is deemed to have been
          received by the addressee:  (i) if sent by registered airmail , on the
          seventh  business day after posting and (ii) if sent by e-mail or fax,
          with confirmation of the reception.

          12.2  ENTIRE AGREEMENT. This Agreement supersedes any previous written
                or oral agreement between the Parties in relation to the matters
                dealt with in this  Agreement  and contains the whole  agreement
                between  the  parties  relating  to the  subject  matter of this
                Agreement  at the date  hereof  to the  exclusion  of any  terms
                implied by law which may be  excluded  by  contract.  Each Party
                acknowledges  that it has not been  induced  to enter  into this
                Agreement by any  representation,  warranty or  undertaking  not
                expressly  incorporated into it. No supplement,  modification or
                discharge  of this  Agreement  is  binding  unless  executed  in
                writing by authorized officers of both parties.

          12.3  NO WAIVER.  Any failure or delay by either party in  exercising,
                any right,  power or remedy in  connection  with this  Agreement
                will  not be  construed  as a  waiver  of that  right,  power or
                remedy. The rights, powers, and remedies in connection with this
                Agreement are  cumulative and not exclusive of any other rights,
                powers, or remedies provided by law or otherwise.

          12.4  SEVERABILITY.  The invalidity or unenforceability for any reason
                of any part of this Agreement will neither  prejudice nor affect
                the  validity  or

                                       13
<PAGE>

                enforceability of any other part of this Agreement.

          12.5  ASSIGNMENT.  Except as  otherwise  provided  in this  Agreement,
                during the Term, any content,  rights and obligations under this
                Agreement  will not be  assigned or  transferred  in whole or in
                part by either party  without the prior  written  consent of the
                other party.  Any attempted  assignment in contravention of this
                Agreement will be void and of no effect.

          12.6  COUNTERPARTS.   This   Agreement   will  be   executed   in  two
                counterparts each of which when executed will be an original and
                together will constitute one and the same instrument.

                                       14
<PAGE>

IN WITNESS WHEREOF, Bionovo and UBC have caused this Agreement to be executed by
their  respective  duly  authorized  representatives  as of the date first above
written.

     Signed on behalf of:                 Signed on behalf of:
     BIONOVO INC., U.S.A.                 UNITED BIOTECH CORPORATION

     By:                                  By:
         ---------------------------          -----------------------------
         Isaac Cohen                          C.C. Lee
         Co-Founder and Chief                 Chairman
         Scientific Officer

Date: November 6, 2003                        Date: November 6, 2003

                                       15
<PAGE>

                                    EXHIBIT A

                          DESCRIPTION OF THE TECHNOLOGY

The technology is the production  procedure for MF101 and BZL101 as indicated in
the U.S. FDA- IND and the complete IND package submitted to the US FDA.

                                       16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]